{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:06Z","timestamp":1786987746313,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA033302"],"award-info":[{"award-number":["K23DA033302"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA025074"],"award-info":[{"award-number":["R01DA025074"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE 1144083"],"award-info":[{"award-number":["DGE 1144083"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.drugalcdep.2017.06.020","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T23:16:28Z","timestamp":1500419788000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6762-7586","authenticated-orcid":false,"given":"L. Cinnamon","family":"Bidwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollis C.","family":"Karoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent. E.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"A.P.A","year":"2013"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1037\/0022-006X.62.3.488","article-title":"Structural equation analyses of clinical subpopulation differences and comparative treatment outcomes: characterizing the daily lives of drug addicts","volume":"62","author":"Aiken","year":"1994","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1521-0391.2013.00325.x","article-title":"Associations between attention deficit hyperactivity disorder symptom domains and DSM-IV lifetime substance dependence","volume":"22","author":"Ameringer","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/thx.2007.090647","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial","volume":"63","author":"Aubin","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2015.19284","article-title":"Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial","volume":"315","author":"Baker","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0030","series-title":"Attention-deficit Hyperactivity Disorder: A Clinical Workbook","author":"Barkley","year":"1998"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0035","series-title":"Manual for the Beck Anxiety Inventory","author":"Beck","year":"1990"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0040","series-title":"Manual for the BDI-II","author":"Beck","year":"1996"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0045","series-title":"EQS 6 Structural Equations Program Manual","author":"Bentler","year":"2006"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4155\/cli.13.34","article-title":"The importance of considering ADHD in smoking cessation clinical trials","volume":"3","author":"Bidwell","year":"2013","journal-title":"Clin. Invest."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1037\/a0035369","article-title":"Associations of attention-deficit hyperactivity disorder symptom dimensions with smoking deprivation effects in adult smokers","volume":"28","author":"Bidwell","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1037\/0278-6133.24.2.133","article-title":"Condom use among high-risk adolescents: testing the influence of alcohol use on the relationship of cognitive correlates of behavior","volume":"24","author":"Bryan","year":"2005","journal-title":"Health Psychol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0065","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1016\/j.bmcl.2005.08.035","article-title":"3,5-Bicyclic aryl piperidines: a novel class of alphbeta2 neuronal nicotinic receptor partial agonists for smoking cessation","volume":"15","author":"Coe","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0070","series-title":"Applied Multiple Regression\/correlation Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0075","first-page":"67","article-title":"Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)","volume":"32","author":"Conners","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1207\/s15327752jpa6801_7","article-title":"Stability and change in personality assessment: the revised NEO Personality Inventory in the year 2000","volume":"68","author":"Costa","year":"1997","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0085","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1080\/14622200802443536","article-title":"Smoking cessation and inattention or hyperactivity\/impulsivity: A post hoc analysis","volume":"10","author":"Covey","year":"2008","journal-title":"Nicotin Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0090","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/ntr\/ntr087","article-title":"Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate","volume":"13","author":"Covey","year":"2011","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/npp.2015.305","article-title":"Varenicline-induced elevation of dopamine in smokers: a preliminary [(11)C]-(+)-PHNO PET Study","volume":"41","author":"Di Ciano","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00213-009-1661-x","article-title":"Impulsivity and cigarette craving: differences across subtypes","volume":"207","author":"Doran","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archpsyc.64.10.1145","article-title":"Prospective effects of attention-deficit\/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse","volume":"64","author":"Elkins","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0110","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1111\/bph.12690","article-title":"Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens","volume":"171","author":"Feduccia","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0115","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jpepsy\/jsm051","article-title":"Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood","volume":"32","author":"Fuemmeler","year":"2007","journal-title":"J. Pediatr. Psychol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0125","first-page":"661","article-title":"Tobacco smoking in individuals with attention-deficit hyperactivity disorder: epidemiology and pharmacological approaches to cessation","volume":"23","author":"Gray","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14622200110050411","article-title":"Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome","volume":"3","author":"Hall","year":"2001","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1037\/a0015657","article-title":"Nicotine deprivation and trait impulsivity affect smokers' performance on cognitive tasks of inhibition and attention","volume":"17","author":"Harrison","year":"2009","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0140","series-title":"Structural Equation Modeling with LISREL: Essentials and Advances","author":"Hayduk","year":"1987"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0145","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14622200500125310","article-title":"Preliminary evidence of the association between the history of childhood attention-deficit\/hyperactivity disorder and smoking treatment failure","volume":"7","author":"Humfleet","year":"2005","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0160","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/archpsyc.62.10.1142","article-title":"Association between smoking and attention-deficit\/hyperactivity disorder symptoms in a population-based sample of young adults","volume":"62","author":"Kollins","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00213-012-2937-0","article-title":"Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder","volume":"227","author":"Kollins","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14622200801901971","article-title":"Dimensions of depressive symptoms and smoking cessation","volume":"10","author":"Leventhal","year":"2008","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00004583-199706000-00009","article-title":"Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study","volume":"36","author":"Levy","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0180","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0185","first-page":"343","article-title":"Moderators of smoking cessation outcomes in a randomized-controlled trial of Varenicline versus placebo","volume":"14","author":"Littlewood","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0190","series-title":"Structural Equation Modeling: Concepts, Issues, and Applications","first-page":"16","article-title":"Model specification: procedures, strategies, and related issues","author":"MacCallum","year":"1995"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0195","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1037\/0033-2909.114.2.376","article-title":"Statistical difficulties of detecting interactions and moderator effects","volume":"114","author":"McClelland","year":"1993","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0200","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1196\/annals.1441.016","article-title":"ADHD and smoking: from genes to brain to behavior","volume":"1141","author":"McClernon","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0205","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ntr\/ntr073","article-title":"Smoking withdrawal symptoms are more severe among smokers with ADHD and independent of ADHD symptom change: results from a 12-day contingency-managed abstinence trial","volume":"13","author":"McClernon","year":"2011","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0210","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.166.15.1561","article-title":"Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up","volume":"166","author":"Nides","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0215","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: A systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0225","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0230","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40263-014-0208-9","article-title":"Targeting the nicotinic cholinergic system to treat attention-deficit\/hyperactivity disorder: rationale and progress to date","volume":"28","author":"Potter","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0235","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the \u03b1 4 \u03b2 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0240","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jsat.2005.02.002","article-title":"Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy","volume":"28","author":"Rukstalis","year":"2005","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0245","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1037\/1082-989X.7.2.147","article-title":"Missing data: our view of the state of the art","volume":"7","author":"Schafer","year":"2002","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0250","series-title":"Experimental and Quasi-experimental Designs for Generalized Causal Inference","author":"Shadish","year":"2002"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1360-0443.2007.02083.x","article-title":"Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness","volume":"103","author":"Stapleton","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1749-6632.2001.tb05783.x","article-title":"Attention deficit\/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations","volume":"931","author":"Sullivan","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004583-200207000-00011","article-title":"Association of attention-deficit\/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents","volume":"41","author":"Tercyak","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0270","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.drugalcdep.2005.04.002","article-title":"Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls","volume":"80","author":"Tidey","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0275","series-title":"Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline","author":"USDHHS","year":"2008"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0280","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2009.1308","article-title":"Evaluating dopamine reward pathway in ADHD: Clinical implications","volume":"302","author":"Volkow","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0285","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1592\/phco.27.10.1440","article-title":"Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine","volume":"27","author":"Whitley","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0290","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1037\/a0027347","article-title":"Validity of DSM-IV attention deficit\/hyperactivity disorder symptom dimensions and subtypes","volume":"121","author":"Willcutt","year":"2012","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.drugalcdep.2017.06.020_bib0295","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopsych.2011.07.024","article-title":"Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens","volume":"71","author":"Zhang","year":"2012","journal-title":"Biol. Psychiatry"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617303447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617303447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:53:45Z","timestamp":1759827225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617303447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":59,"alternative-id":["S0376871617303447"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.020","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}